TABLE 1.
Key demographic and baseline clinical characteristics in Asian and non‐Asian patients in the Pola‐R‐CHP treatment arm in POLARIX (intent‐to‐treat population).
| Asian | Non‐Asian | |
|---|---|---|
| Pola‐R‐CHP (n = 81) | Pola‐R‐CHP (n = 359) | |
| Median age, years | 63.0 | 66.0 |
| Male, n (%) | 42 (51.9) | 197 (54.9) |
| Mean weight at baseline, kg (SD) | 60.4 (13.6) | 79.5 (19.6) |
| ECOG PS at baseline, n (%) | ||
| 0 | 42 (51.9) | 133 (37.0) |
| 1 | 29 (35.8) | 170 (47.4) |
| 2 | 10 (12.3) | 56 (15.6) |
| Ann Arbor stage, n (%) | ||
| I | 1 (1.2) | 1 (0.3) |
| II | 12 (14.8) | 33 (9.2) |
| III | 17 (21.0) | 107 (29.8) |
| IV | 51 (63.0) | 218 (60.7) |
| IPI score, n (%) | ||
| 2 | 31 (38.3) | 136 (37.9) |
| 3–5 | 50 (61.7) | 223 (62.1) |
| Bulky disease status, n (%) | ||
| Absent | 55 (67.9) | 192 (53.5) |
| Present | 26 (32.1) | 167 (46.5) |
| Bone marrow involvement at diagnosis, n (%) | n = 80 | n = 349 |
| Indeterminate | 0 | 11 (3.1) |
| Negative | 64 (79.0) | 278 (77.4) |
| Positive | 16 (19.8) | 60 (16.7) |
| DEL by IHC, n (%) | n = 69 | n = 293 |
| DEL | 24 (34.8) | 115 (39.2) |
| Non‐DEL | 45 (65.2) | 178 (60.8) |
| Double/triple‐hit lymphoma, n (%) | n = 67 | n = 264 |
| DH/TH+ | 3 (4.5) | 23 (8.7) |
| DH/TH− | 64 (95.5) | 241 (91.3) |
| COO, n (%) | n = 53 | n = 277 |
| ABC | 26 (49.1) | 76 (27.4) |
| GCB | 21 (39.6) | 163 (58.8) |
| Unclassified | 6 (11.3) | 38 (13.7) |
Abbreviations: ABC, activated B‐cell; COO, cell of origin; DEL, double‐expressor lymphoma; DH, double‐hit; GCB, germinal center B‐cell; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IHC, immunohistochemistry; IPI, International Prognostic Index; Pola‐R‐CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, prednisone; SD, standard deviation; TH, triple‐hit.